Please assess the completion status of the following clinical trial:

Trial Title: Explore Efficacy of FMT Treating Childhood ASD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with ASD. Diagnostic criteria: diagnosed by pediatric psychiatrists in accordance with the criteria in the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V), Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview-Revised (ADI-R);~2. Patients with moderate to severe gastrointestinal symptoms which are not life-threatening and do not require immediate surgery;~3. Patients aged 3-17 years, male or female;~4. Patients who are suitable for receiving oral FMT capsules, and able to swallow the capsules without chewing;~5. Patients who are able to complete the study as required by the trial protocol;~6. Patients without known immunodeficiency diseases;~7. Subjects and/or their guardians are able to fully understand the informed consent of the trial, and voluntarily sign the informed consent form.~Exclusion Criteria：~1. Patients diagnosed with severe malnutrition;~2. Patients depend on tube feeding (liquid food);~3. Patients with a serious gastrointestinal disease requiring immediate treatment (or life-threatening);~4. Patients with primary immunodeficiency disease during screening;~5. Patients with a single-gene disorder;~6. Patients with a history of severe allergies;~7. Patients with severe fever and/or serious infection within 7 days prior to enrollment;~8. Patients with renal insufficiency and liver dysfunction (or creatinine \> 2 mg/dl, direct bilirubin \> 2 mg/dl);~9. Subjects with congenital or acquired immunodeficiency or immunosuppression (e.g., neoplastic disease or organ transplant) who have received or are undergoing chemotherapy, or have been diagnosed with HIV;~10. Patients with inflammatory bowel disease, celiac disease, large intestine irritation or eosinophilia, esophagitis, eosinophilic gastroenteritis or similar diseases;~11. Subjects with severe sensory or motor disorders (e.g., blindness, deafness, seizures, cerebral palsy);~12. Patients who are participating in other clinical studies, or have received interventions in other interventional clinical studies within 4 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- FMT (Type: EXPERIMENTAL): 20 subjects will be enrolled in this arm to receive FMT treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).